Paper36009355
Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.
Jezernik G and 2 others. Biomedicines, 2022. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis. Papers, record 36009355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36009355
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P3-0067 | Slovenian Research Agency | PubMed | ||
| J3-9258 | Slovenian Research Agency | PubMed |
Source PubMed
References154
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25292482 | IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis. | Int J Rheum Dis | 2014 | https://conductscience.org/library/papers/25292482 | PubMed |
| 2 | 20444755 | Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. | Ann Rheum Dis | 2010 | https://conductscience.org/library/papers/20444755 | PubMed |
| 3 | 17967830 | B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders. | Ann Rheum Dis | 2008 | https://conductscience.org/library/papers/17967830 | PubMed |
| 4 | 19327235 | The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. | Clin Exp Rheumatol | 2009 | https://conductscience.org/library/papers/19327235 | PubMed |
| 5 | 33691749 | Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. | Arthritis Res Ther | 2021 | https://conductscience.org/library/papers/33691749 | PubMed |
| 6 | 16855168 | Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. | Ann N Y Acad Sci | 2006 | https://conductscience.org/library/papers/16855168 | PubMed |
| 7 | 21801431 | Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. | Arthritis Res Ther | 2011 | https://conductscience.org/library/papers/21801431 | PubMed |
| 8 | 34796837 | Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. | Clin Exp Rheumatol | 2022 | https://conductscience.org/library/papers/34796837 | PubMed |
| 9 | 25546405 | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. | PLoS One | 2014 | https://conductscience.org/library/papers/25546405 | PubMed |
| 10 | 24253594 | Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. | Pharmacogenet Genomics | 2014 | https://conductscience.org/library/papers/24253594 | PubMed |
| 11 | 16720636 | The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. | Rheumatology (Oxford) | 2007 | https://conductscience.org/library/papers/16720636 | PubMed |
| 12 | 22550316 | Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. | Ann Rheum Dis | 2012 | https://conductscience.org/library/papers/22550316 | PubMed |
| 13 | 19262425 | Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. | Pharmacogenet Genomics | 2009 | https://conductscience.org/library/papers/19262425 | PubMed |
| 14 | 20032971 | CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20032971 | PubMed |
| 15 | 26526676 | Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. | Clin Rheumatol | 2015 | https://conductscience.org/library/papers/26526676 | PubMed |
| 16 | 24728031 | Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. | Rheumatol Int | 2014 | https://conductscience.org/library/papers/24728031 | PubMed |
| 17 | 28010726 | Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. | Arthritis Res Ther | 2016 | https://conductscience.org/library/papers/28010726 | PubMed |
| 18 | 28112584 | Association of Fcgamma receptor type 2A and 3A genotypes with rheumatoid arthritis in Chinese population. | Pharmacogenomics | 2017 | https://conductscience.org/library/papers/28112584 | PubMed |
| 19 | 27532898 | Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study. | Mol Med | 2016 | https://conductscience.org/library/papers/27532898 | PubMed |
| 20 | 18930989 | Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. | Ann Rheum Dis | 2009 | https://conductscience.org/library/papers/18930989 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39337694 | Discovery of Novel Biomarkers with Extended Non-Coding RNA Interactor Networks from Genetic and Protein Biomarkers. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337694 | PubMed |
| 37631238 | Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37631238 | PubMed |
Genes290
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36009355
GET https://conductscience.org/api/papers/v1/36009355/references?page=2